Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Employment agrmnt
Quarterly results
Acq. announced

SomaLogic, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 425 Form 425 - Prospectuses and communications, business combinations:
10/04/2023 425 Form 425 - Prospectuses and communications, business combinations:
10/04/2023 425 Form 425 - Prospectuses and communications, business combinations:
10/04/2023 425 Form 425 - Prospectuses and communications, business combinations:
10/04/2023 425 Form 425 - Prospectuses and communications, business combinations:
10/04/2023 8-K Acquisition/merger/asset purchase announced
Docs: "AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., STANDARD BIOTOOLS INC., and MARTIS MERGER SUB, INC.",
"Key Employee Severance Plan Amended and Restated Participation Notice",
"Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools",
"Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; the expected benefits of the merger, including estima...",
"Schedule A Schedule B Schedule C",
"Schedule A",
"VOTING AGREEMENT This Voting Agreement , dated as of October 4, 2023, is by and among SomaLogic, Inc., a Delaware corporation , Standard BioTools Inc., a Delaware corporation , Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent , and the persons listed on the attached Schedule A who are signatories to this Agreement . RECITALS WHEREAS, concurrently herewith, the Company, Parent and Merger Sub are entering into an Agreement and Plan of Merger ; WHEREAS, as of the date of this Agreement, each Stockholder is the record and/or “beneficial owner” of the approximate number of shares of Company Common Stock set forth on Schedule A opposite such Stockholder’ s name , such Stockholder’ s “ Covered Shares ”); WHEREAS, as a condition and inducement to the willingn..."
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "SomaLogic, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Unaudited Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenue Assay services revenue $ 16,597 $ 10,931 $ 35,016 $ 29,731 Product revenue 2,909 714 4,095 1,167 Collaboration revenue 762 762 1,525 1,525 Other revenue 200 1,737 211 4,701 Total revenue 20,468 14,144 40,847 37,124 Operating expenses Cost of assay services revenue 9,677 6,571 21,359 17,951 Cost of product revenue 1,498 506 2,132 778 Research and development 10,815 17,636 24,882 31,436 Selling, general and administrative 29,573 36,812 63,762 67,627 Total operating expenses 51,563 61,525 112,135 117,792 Loss from operations Other income Interest income and other, net 5,798 838 10,723 1,047 Change in fair value of ..."
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SomaLogic Announces Chief Financial Officer Transition"
05/11/2023 8-K Quarterly results
Docs: "SomaLogic Reports First Quarter 2023 Financial Results"
05/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 8-K/A Quarterly results
04/14/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
04/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Retention Bonus Amount Retention Date"
03/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/28/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Arbeitsvertrag / Employment Agreement"
03/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ORDER ENTERED BY THE DELAWARE COURT OF CHANCERY ON MARCH 6, 2023"
02/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G BlackRock Inc. reports a 5.5% stake in SomaLogic, Inc.
01/10/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "CERTAIN INFORMATION IDENTIFIED WITH THE MARK “”, “” AND “” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Amendment #2 to Master Collaboration Agreement Reference is hereby made to the Master Collaboration Agreement , dated September 20, 2019, by and between SomaLogic Operating Co., Inc. and Novartis Pharma AG , as amended by the First Amendment, dated June 15, 2021. This Amendment #2 to Master Collaboration Agreement , dated January 4, 2023 ) amends the Agreement as set forth herein. 1. Section 1.2.2 . Section 1.2.2 is amended as follows: in Subsection 1.2.2.b delete “joint” in two occurrences; delete the entire content of Subsection 1.2.2.e and replace it with “to obtain SomaLogic’ s c..."
01/09/2023 8-K Quarterly results
12/14/2022 SC 13D/A CMLS Holdings II LLC reports a 12.4% stake in SomaLogic, Inc.
11/18/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/18/2022 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy